Press Releases & Events


12 April 2019

Fidia Pharma USA Inc Announces Expansion into the Dietary Supplement Market with Launch of CartiJoint™ FORTE

CartiJoint™ FORTE is the First Product in Fidia’s New Dietary Supplement Portfolio; Uniquely formulated with bioactive Bio-Curcumin Curcugreen™

12 March 2019

Fidia Pharma USA Inc Announces Expansion into Regenerative Medicine Markets with Launch of NuDYN™

Florham Park, NJ, March 12, 2019 – NuDYN™ is the First Product in Fidia’s New Orthobiologics Portfolio; A Novel Acellular Amnion-Derived Injectable Allograft

18 March 2018

Italian pharmaceutical R&D excellence at the 33rd Congress of the European Association of Urology

Copenhagen, March 18, 2018 – Fidia farmaceutici today announced the positive results from a phase II trial evaluating efficacy and tolerability of Oncofid®P-B, an innovative Paclitaxel-Hyaluronan Bioconjugate targeted to cancer cells, in patients with primary or recurrent Ta G1-G2 papillary bladder cancer.


Recent Events

5 July 2016

Fidia Presents New Data on HYMOVIS® , a Breakthrough in Viscoelastic Technology, at the American Orthopaedic Society for Sports Medicine 2016 Annual Meeting

HYMOVIS® is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties; new data demonstrating long-term benefits of Hymovis® in alleviating osteoarthritis knee pain and stiffness and improving physical function and quality of life will be presented.
PARSIPPANY, N.J., July 5, 2016 – Fidia Farmaceutici S.p.A., a world leader

Our Four Leading Principles:





Have Knee Pain?

Diagnosed with OSTEOARTHRITIS (OA) of the knee?

You may be eligible to participate in a clinical trial